The JN1 variant harbors Leu455Ser and three mutations in non-spike proteins contributing to increased transmissibility and immune escape ability. Pseudovirus assays have shown that the infectivity of JN.1 is significantly higher than its predecessor XBB.1.5 from omicron family (1). JN.1 is about 3 to 5 times less susceptible to neutralizing antibodies than the XBB.1.5 variant that is in the updated booster raising concerns about its potential impact on public health (2)
No takes yet. Share an insight, caveat, or question.
Rizwan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: